Personalized Neo-Antigen Peptide Vaccine for Cancer Treatment
Phase 1
25
about 5.4 years
18+
1 site in WA
What this study is about
This trial is testing a personalized vaccine to treat advanced cancers. The vaccine combines multiple patient-specific neoantigens, potentially boosting the immune system's ability to fight cancer cells. It aims to determine if this vaccine is safe when given with an adjuvant called poly ICLC.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Neoantigen Peptide Vaccine
- 2.Receive Nivolumab
- 3.Take Poly ICLC
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
vaccine, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
injection, infusion
Primary: Incidence of adverse events
Secondary: Best overall response, Progression-free survival
biopsy, diagnostic, imaging
Oncology